Antibacterial therapy of acute exacerbated chronic bronchitis
Abstract
An early therapy of the acute exacerbation is important for the long-term prognosis of chronic bronchitis. The aim of the therapy is to stop the progressive damage of the bronchial mucosa. The typical clinical symptoms and the knowledge of the usual pathogens (in at least 80% hemophilus influenzae and streptococcus pneumoniae) allow a "blind" chemotherapy with aminopenicillins, tetracyclines and the trimethoprim-sulphonamide combination as medication of choice. The treatment is successful when the purulent sputum turns mucoid within 2 to 5 days and the symptoms improve. If this does not happen, culture and antibiogram should be made and chemotherapy chosen according to the findings. The acute exacerbation can be complicated by an airway obstruction. In this case the short-term application of glucocorticoids in combination with bronchodilators and secretolytics is suggested.
Read the paper
Related studies
- Impact of antibiotics on the human microbiome and consequences for host health
- Antibiotics in the clinical pipeline in October 2019
- The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan
- Research Communications of the 32nd ECVIM-CA Online Congress
- Singlet-Oxygen Therapy. Scientific And Methodological Materials
- Artificial Intelligence in Pharmacovigilance
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.